Pancreatic Cancer News
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings.
Risks for pancreatitis, pancreatic cancer higher in Korean patients with newly diagnosed T2DM.
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Continuous increase in risk of pancreatic cancer with elevating fasting glucose, even within normal range.
Cyst classifier test is based on clinical and imaging features, genetic and biochemical markers.
Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.
The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy.
Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.
Olaparib maintenance therapy improved PFS in patients with metastatic pancreatic adenocarcinoma characterized by a deleterious BRCA1/2 mutation.
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Study results suggest a new combination regimen could become the standard of care for some patients.
Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.
The bacterial strains found in oral samples may be representative of the types of strains that exist in the tumor microbiomes of patients with pancreatic or GI disease.
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.
Pancreatic risk rises in a dose-response manner with increasing number of affected first-degree relatives.
Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.